Interventional Cardiology
Interventional Cardiology
At Biosensors, we strive to make an impact in patients’ lives by continually investing in and developing pioneering medical technology. Being at the forefront of new and innovative solutions helps us respond to the changing needs of the interventional cardiology market. We are the first company to offer a commercially available abluminal drug-eluting stent with a biodegradable limus technology.
Our new generation drug-eluting stents were created using the most advanced medical technology in its field. They offer patients many benefits by combining:
-
Proven safety of a DES with:
- An abluminal coating that promotes an endothelial coverage similar to a bare metal stent (BMS), provides more targeted drug release and reduces the systemic exposure
- A biodegradable polymer that is absorbed after 6 to 9 months*
- Proven efficacy of our drug, BA9™, that has 10 times more lipophilicity than sirolimus, resulting in a more targeted release to the vessel wall
- Enhanced deliverability** with advanced stent design. The additional improvement with BioMatrix NeoFlex™ is provided by an even better delivery system
Axxess™ is the first BA9™- eluting dedicated bifurcation stent
Featuring our abluminal4 biodegradable PLA / BA9™ technology, and complementing the existing BioMatrix family of products.
Bare Metal Stents
Based on the advanced design technology behind our proprietary S-Stent™ platform, Gazelle™3 is our bare metal stent (BMS) that provides cardiologists with:
- Flexible stent design with the Quatrature Link™ technology for excellent deliverability
Biosensors’ balloon dilatation catheter achieves the right balance of push-track-cross to meet clinical needs.
The MultiPleat™ folding technology provides excellent cross and re-cross properties to facilitate use in complex procedures.
| * | In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months. Data on file at Biosensors International |
| ** | Deliverability defined as a combination of flexibility, trackability and pushability |
| 3. | Commercialized under the name S-Stent™ in Japan. |
| 4. | The coating is applied primarily on the abluminal surface. |
CAUTION: The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.
Biosensors’ interventional cardiology products, including BioMatrix Flex™, BioMatrix™, Axxess™, BioFreedom™, Gazelle™, Juno™, S-Stent™, Powerline™, Quadrature Link™ and MultiPleat™, are not available for sale in the United States and certain other countries. BioFreedom™ is an investigational device. All other trademarks are the property of their respective owners.
BioMatrix Flex, BioMatrix, Axxess, BioFreedom, Gazelle, Juno, S-Stent, Powerline, Quadrature Link and MultiPleat are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and certain other countries. All cited trademarks are the property of their respective owners.